key: cord-0801235-p67f3sya authors: Shurin, Michael R; Morris, Alison; Wells, Alan; Wheeler, Sarah E title: Assessing Immune Response to SARS-CoV-2 Infection date: 2020-06-11 journal: Immunotargets Ther DOI: 10.2147/itt.s264138 sha: 1657a4934f1c11a4f450853ee5b8bec83e1b7c56 doc_id: 801235 cord_uid: p67f3sya nan pathways, skin and the immune system in some patients. Interestingly, both lymphopenia and hyperactivation of the immune responses are reported in COVID-19 patients. Therefore, from the immunological point of view, the important question is: What do we need to know about COVID-19 immunity, and thus what should we measure in these patients? Noticeably, the immune responses induced by SARS-CoV-2 infection seem to be in two-stages. As most of the infected individuals develop only mild or no clinical symptoms, it is conceivable that during the incubation and non-severe stages, a specific adaptive immune response is required to eliminate the virus and to preclude disease progression to severe stages. Such a robust immune response, as noted by virus-specific immunoglobulin production in these individuals, is associated with clinical recovery of most SARS-CoV-2-infected patients without severe respiratory symptoms. 7, 8 However, when a protective immune response is impaired, virus propagates and massive destruction of the affected tissues occurs, particularly in organs with high ACE2 expression. 9 At this stage, hyperactivation of a few subsets of immune cells and the cytokine release syndrome (CRS, "cytokine storm") induces lung, intestine and kidney damage. In addition, liver injury has also been reported to occur during the course of the disease in severe cases as is seen in SARS-CoV and MERS-CoV. 10 A total of 14 cytokines, from 48 analyzed, were significantly elevated in plasma in patients with COVID-19. 11 Importantly, these cytokines exhibited dissimilar expression profiles in patients with different disease severity: for instance, levels of IP-10, MCP-3, HGF, MIG and MIP-1α were significantly higher in critically ill patients when compared with the expression in patients with severe or moderate disease. Also, IP-10 and MCP-3 were revealed to be outstanding predictors for the progression of COVID-19 disease. Interestingly, ACE2 was shown to function as an interferon-stimulated gene in human barrier tissue epithelial cells 12 suggesting that SARS-CoV-2 may exploit IFNinduced increase in ACE2 expression, a crucial cellprotective factor in lung injury, to augment infection. Furthermore, serum IL-6, IL-10 and TNF-α concentrations negatively correlated with reduced total T cells, CD4 + and CD8 + T cells, and survival of COVID-19 patients. 13 T cells from these patients expressed high levels of PD-1, which was particularly seen as patients progressed from prodromal to overtly symptomatic stages. Thus, it is possible that the cytokine release may drive the depletion and exhaustion of T cells. Together with the fact that low T cell number and exhausted T cells can leave patients more susceptible to secondary infection, these results suggest that it is important now to focus on subpopulations of T cells in order to discover their vulnerability and their role in disease progression and recovery. Recent data demonstrated reduced COVID-19 severity in patients with respiratory allergies potentially due to the reduction in ACE2 expression in allergic individuals, 14 suggesting the need to expansively assess the role of type 2 immune regulation in the pathogenesis of SARS-CoV-2 infection. At the same time, an excessive immune response contributes to SARS-CoV-2 pathogenesis and COVID-19 lethality. The rapid viral replication of SARS-CoV-2 may cause fatal inflammatory responses and acute respiratory distress syndrome (ARDS) in patients. For instance, during virus replication, the released coronavirus nucleocapsid dimers may interact with mannose-binding lectin-associated serine proteases. This interaction induces over-activation of the complement system and promotes cell lysis leading to further elevation of pro-inflammatory cytokines, characterized as cytokine storm. 15 Tissue damage, particularly if associated with disproportionate inflammation and CRS, may dysregulate the peripheral tolerance machinery and allow initiation or hastening of autoimmune pathways. It is also possible that despite the lymphocytopenia often seen in severe COVID-19 patients, hyperactivation of virus-specific CD8+ and CD4+ T cells during SARS-CoV-2 infection and massive destruction of infected cells may result in the development of autoimmune pathology after patient recov- Again, a comprehensive analysis of T cell subsets in COVID-19 patients, especially after recovery, is justified to predict and minimize outcomes of immune dysregulation during infection. In spite of a growing body of immunological data associated with SARS-CoV-2 infection, it is still not completely understood how the infection is cleared. 16 If SARS-CoV-2, similar to other coronaviruses, induces an acute infection which is then completely cleared by the immune system, then the majority of recovered individuals should acquire at least a temporary immunity and be protected from a repeated infection for some time. Another scenario is viral latency, when the virus may lie dormant within a cell as the viral genome has not been fully eradicated. The virus is still able to reactivate via external activators, as seen in herpes simplex virus, which commonly infects an individual for life. Another scenario is a chronic infection, such as in the case of viral hepatitis and HIV, when a virus persists for a continued period and causes long-term inflammation and damage. This limited understanding of SARS-CoV-2 behavior suggests the necessity to develop verified immunoassays to assess the circulation of both anti-viral antibodies and viral proteins (antigens) as in the case of HBV and HIV infections. As many unknowns remain about antibody tests, determination of several subclasses of immunoglobulins -IgG, IgM and IgA, recognizing at least SARS-CoV-2 specific spike and nucleocapsid proteinsis urgently needed to unravel the development and stability of immune response to SARS-CoV-2 infection. These clinical data should support the development of alternative fast, reliable and non-expensive testing of the neutralizing potential of tested anti-viral antibodies. This information also is needed for a better understanding of the applicability of a phenomenon known as antibody-dependent enhancement, when pathogen-specific antibodies can promote pathology, 17 to SARS-CoV-2 infection and COVID-19 severity. The results of wide antibody testing should provide information on disease prevalence and the frequency of asymptomatic infections. Finally, the determination of spike, nucleocapsid and envelop proteins of SARS-CoV-2 in serum/plasma samples is also urgently needed to support expanded screening of different populations of people for epidemiologic, predictive, and risk evaluating studies. Further elucidation of these complex clinical data will identify novel diagnostic and therapeutic strategies to more effectively control this pandemic and prevent its potential recurrence. The authors report no conflicts of interest in this work. ImmunoTargets and Therapy is an international, peer-reviewed open access journal focusing on the immunological basis of diseases, potential targets for immune based therapy and treatment protocols employed to improve patient management. Basic immunology and physiology of the immune system in health, and disease will be also covered. In addition, the journal will focus on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors. ImmunoTargets and Therapy 2020:9 SARS and MERS: recent insights into emerging coronaviruses Coronaviruses: severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus in travelers Coronaviruses, a new group of animal RNA viruses History and recent advances in coronavirus discovery Human coronaviruses: what do they cause? Antivir Ther SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Treatment of COVID-19: old tricks for new challenges Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 COVID-19 infection: the perspectives on immune responses Liver injury in COVID-19: management and challenges Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19 SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is enriched in specific cell subsets across tissues Reduction and functional exhaustion of T cells in patients with Coronavirus disease 2019 (COVID-19) Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2 Structures and functions of coronavirus proteins: molecular modeling of viral nucleoprotein Profile of a killer: the complex biology powering the coronavirus pandemic The potential danger of suboptimal antibody responses in COVID-19